Benitec Biopharma reports Q3 FY2025 net loss of $9.4M; cash $103.6M; BB-301 low-dose cohort completed

Benitec Biopharma Inc.

2025-Q3 EPS reported -$0.63 vs consensus -$0.38 ▼ miss (-67.7%)

Net loss of $9.4M ($0.24/share) vs $4.3M ($0.23/share) in prior year; expenses rose to $10.2M on higher R&D and G&A.
Cash and cash equivalents $103.6M as of March 31, 2025, up from $50.9M at June 30, 2024.
BB-301: sixth and final subject in Cohort 1 (low dose) treated safely in April 2025; enrollment at higher dose expected later this year.
Additional clinical study updates for Cohort 1 subjects planned for Q4 calendar 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.